Barings LLC purchased a new position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 33,854 shares of the company’s stock, valued at approximately $730,000.
Other large investors also recently made changes to their positions in the company. PointState Capital LP acquired a new position in Teva Pharmaceutical Industries in the second quarter valued at $161,826,000. Renaissance Technologies LLC increased its stake in Teva Pharmaceutical Industries by 348.1% in the second quarter. Renaissance Technologies LLC now owns 4,036,863 shares of the company’s stock valued at $98,177,000 after purchasing an additional 3,135,900 shares during the period. Point72 Asset Management L.P. acquired a new position in Teva Pharmaceutical Industries in the second quarter valued at $90,746,000. Swiss National Bank increased its stake in Teva Pharmaceutical Industries by 8.8% in the second quarter. Swiss National Bank now owns 3,686,899 shares of the company’s stock valued at $89,665,000 after purchasing an additional 298,600 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its stake in Teva Pharmaceutical Industries by 10.7% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,991,342 shares of the company’s stock valued at $72,749,000 after purchasing an additional 288,406 shares during the period. Hedge funds and other institutional investors own 64.73% of the company’s stock.
A number of research analysts have commented on the stock. Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the company an “underperform” rating in a research note on Friday. Royal Bank of Canada set a $22.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Friday. Wells Fargo & Co restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Friday. Maxim Group restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday. Finally, Oppenheimer restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday. Five analysts have rated the stock with a sell rating, sixteen have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $21.26.
In related news, insider Deborah A. Griffin sold 2,376 shares of the business’s stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $23.71, for a total transaction of $56,334.96. Following the sale, the insider now owns 2,376 shares of the company’s stock, valued at $56,334.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Iris Beck Codner sold 4,165 shares of the business’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $22.70, for a total transaction of $94,545.50. Following the sale, the executive vice president now directly owns 8,290 shares in the company, valued at approximately $188,183. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,350 shares of company stock worth $239,430. Insiders own 0.43% of the company’s stock.
Shares of NYSE:TEVA opened at $22.59 on Friday. The stock has a market capitalization of $22.97 billion, a PE ratio of 5.75, a PEG ratio of 1.86 and a beta of 0.77. The company has a current ratio of 1.03, a quick ratio of 0.69 and a debt-to-equity ratio of 1.86. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $10.91 and a fifty-two week high of $25.96.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.53 by $0.11. The business had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.54 billion. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.69%. The business’s quarterly revenue was down 19.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.00 earnings per share. On average, equities analysts predict that Teva Pharmaceutical Industries Ltd will post 2.72 earnings per share for the current fiscal year.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
See Also: How Buying a Call Option Works
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.